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Abtract 
Transplants are the only effective therapy for the treatment of advanced liver diseases such as cirrhosis. Given the limi-
ted number of organ donors, regenerative medicine has sought for sources of cells and tissues for replacement therapy. 
Embryonic stem cells are a promising source of material for transplantation because of their exclusive property of being 
expanded indefinitely in culture, thus, they are a source of replacement tissue. Moreover, they are capable of differen-
tiating into practically all cell types, and may be utilized in replacement therapy in various diseases. The liver bud has 
bipotent stem cells that have not yet differentiated into hepatocytes or biliary duct cells; however, they have great po-
tential of proliferation and differentiation. Thus, the challenge is to identify methods that promote their differentiation 
in specific and functional strains. This study aimed to evaluate the role of the progranulin growth factor PGRN during 
the liver development of rats F344, since this growth factor could be utilized in protocols of differentiation of stem cells 
of the liver bud in functional hepatocytes. The results showed that PGRN is present during different periods of hepato-
genesis in F344 rats, and that this growth factor should be involved in the process of differentiation of hepatoblasts into 
hepatocytes after activation by HNF4α , however, PGRN seems not to exert a cellular proliferation function during the 
hepatogenesis. Thus, PGRN can be used in future protocols of liver cell differentiation directed toward cellular therapy 
in Regenerative Medicine. 
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Resumo
Os transplantes são a única terapia eficaz para o tratamento de doenças hepáticas avançadas, como a cirrose. Dado o 
número limitado de doadores de órgãos, a medicina regenerativa tem procurado fontes de células para a terapia de 
substituição. As células embrionárias são uma fonte promissora de material para o transplante devido à sua proprie-
dade exclusiva de serem expandidas indefinidamente em cultura, assim, elas são uma fonte de tecido de substituição. 
Além disso, são capazes de se diferenciar em praticamente todos os tipos celulares, e podem ser utilizadas na terapia de 
substituição em várias doenças. O broto hepático tem células-tronco (CT) bipotenciais que ainda não se diferenciam 
em hepatócitos ou células do ducto biliar, contudo, elas têm um grande potencial de proliferação e de diferenciação. 
Desse modo, o desafio é identificar métodos que promovam sua diferenciação em linhagens específicas e funcionais. 
Este estudo teve como objetivo avaliar o papel do fator de crescimento progranulina (PGRN) durante o desenvolvimen-
to hepático em ratos F344, uma vez que a PGRN poderia ser utilizada em protocolos de diferenciação de CT do broto 
hepático em hepatócitos funcionais. Os resultados mostraram que PGRN está presente durante diferentes períodos da 
hepatogênese em ratos F344, e que a mesma deve estar envolvida no processo de diferenciação de hepatoblastos em he-
patócitos após ativação por HNF4α, no entanto, a PGRN parece não desempenhar uma função de proliferação celular 
durante a hepatogênese. Assim, a PGRN pode ser usada em futuros protocolos de diferenciação de células hepáticas 
voltadas para a terapia celular na medicina regenerativa.
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Introduction
Diseases involving endodermically derived organs, 
particularly the lungs, liver and pancreas, including 
cystic fibrosis, chronic hepatitis and diabetes 
respectively, affect thousands of people in the world. 
Notably, even though the liver has regenerative 
properties, most of the injuries occurring from these 
diseases are extremely destructive, and can cause 
progressive lesions in this organ, and in more severe 
cases, cirrhosis (ALFIERI; MIES, 2001). Thus, repair 
mechanisms become ineffective, and a transplant is 
the only option. However, the insufficient number 
of organ donors and the complexity of the surgical 
procedure, even today are still normally limiting 
factors for this choice of treatment. An alternative 
choice of treatment for these patients is the stimulation 
of the regeneration of the affected tissue in vivo 
or generation of replacement tissue in vitro. This 
research area is referred to as Regenerative Medicine 
(SPENCE; WELLS, 2007).
The use of primary hepatocytes derived from a 
reduced number of cells from an adult liver for cell 
culture could be used as a solution to the limited 
number of human donors. However, it has been 
observed that this cell line does not have a great 
capacity of in vitro proliferation. But this limiting 
factor is not verified in embryonic stem cells, which 
maintain their differentiation potential for several cell 
types and consequently makes them an important 
source for different cell types and cell therapy (PARK; 
LEE, 2005). 
Pre-established liver strain cells, which have a greater 
differentiation potential, are another important source 
(KIYOTA; MATSUSHITA; UEOKA, 2007). Thus, 
the challenge is to identify methods that promote 
differentiation in adult and functional hepatocyte 
strains (SPENCE; WELLS, 2007). These strains can 
become a proposal for the future, not only for the 
treatment of liver diseases, but also in the development 
of new drugs (PAUTON; HAYNES, 2005).
Studies show that progranulin growth factor (PGRN) 
can be involved in differentiation of embryonic cells and 
that it is a growth factor with great potential to induce 
cell proliferation (HE; BATEMAN, 2003) because it 
is involved in embryonic and neonatal development 
(DANIEL et al., 2003), and thus, could be linked to the 
differentiation of hepatoblasts into hepatocytes. 
PGRN is also involved in cell survival (GUERRA et 
al., 2007), in tumorigenesis (TANGKEANGSIRISIN; 
HAYASHI; SERRERO, 2004), in the prevention of 
the frontotemporal lobe degeneration (MACKENZIE 
et al., 2006; PETKAU et al., 2012; WHITWELL et 
al., 2012), and is present (protein and mRNA) in 
the liver and intestine of cirrhotic rats (GUERRA 
et al., 2009). According to Diaz-Cueto et al. (2000), 
inhibition of PGRN action retards blastocyst 
formation, and exogenous PGRN has the ability to 
accelerate the onset of cavitation and is a growth 
factor for trophectoderm epithelial cells. Suzuki et 
al. (2000) show that involvement in the production 
of hypothalamic PGRN leads to a damaged sexual 
differentiation of the masculine hypothalamus.  
Li et al. (2012) showed that high PGRN is associated 
to increased angiogenesis of breast carcinoma. PGRN 
still acts as a promising endogenous neuro-protector 
with anti-apoptosis and anti-inflammatory properties 
utilized in recuperation of motor and neurologic 
functions after cerebral infarct (TAO et al., 2012). 
Studies also suggest that PGRN is involved in the 
advancement of astrocytoma and can be a prognostic 
biomarker for glioblastoma (YILMAZ et al., 2011). It 
is also associated to the degree of liver fibrosis in non-
alcoholic patients (AL-AYADHI; MOSTAFA, 2011). 
The great diversity of functions allotted to PGRN in the 
past few years shows that it needs to be further studied.
 Another protein, Hepatocyte Nuclear Factor-4α 
(HNF-4α) is a transcription factor belonging to the 
steroid hormone receptor subfamily (CHEN et al., 
2010). Studies have demonstrated that HNF-4α acts 
in the cascade of transcription factors that lead to 
liver differentiation and is a hepatocyte marker, which 
was used in this study. 
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PCNA (proliferating cell nuclear antigen), which 
is involved in the mitotic processes, is essential to 
eukaryotic DNA replication and is considered a cell 
proliferation marker, and consequently, it is also present 
in hepatogenesis (TAN et al., 1986; BRAVO et al., 1987; 
PRELICH et al., 1987). PCNA was also studied in this 
research, and the PCNA and HNF4α sites of positivity 
were compared to those of the PGRN.  
Thus, this study aims to elucidate the PGRN growth 
factor during hepatogenesis in different embryonic 
stages of rats (Rattus norvegicus) Fischer 344, 
with the future objective of using it as an agent for 
differentiating embryonic cells into hepatocytes. 
Materials and Methods 
Histological fixation, embedding and processing: 
The embryos used, at 12.5 days of development 
(E12.5); E13.5; E14.5; E15.5; and E16.5, were 
collected and given by the Division of Anatomy of 
the Department of Surgery of School of Veterinary 
Medicine and Animal Science, University of São Paulo 
(SVMAS- USP), Brazil, according to the requirements 
of its Bioethics Committee under the number of 
1377/2008. The biological material was collected and 
fixated in Metacarn (60% methanol, 30% chloroform 
and 10% acetic acid). 
 After a 12-hour fixation, the samples were 
dehydrated in a series of increasing concentrations 
of ethanol (from 70 to 100%) and diaphanized in 
xylene, and then the whole embryo was embedded 
in paraplast® (Paraplast Embedding Media, Paraplast 
Plus, Sigma, Oxford Lab. USA) (JUNQUEIRA, 1995).
Serial slicing at a thickness of 5 µm, obtained on 
a semi-automatic microtome (Leica, RM2165), was 
performed on the entire embryo. The slices were 
adhered to histology slides and left in an oven at 60ºC. 
Detection of PGRN, HNF4α and PCNA antigens: 
The primary antibody anti-PGRN (kindly provided 
by Dr. Andrew Bateman, produced in his laboratory 
– Endocrinology Laboratory/Victoria Hospital/Mc 
Gill/Canada) was used in 5 slices per embryo. The 
histologic sections were collected in silanized slides, 
dewaxed and dehydrated according to standard 
protocol. The slides were submitted to three one-
minute distilled H2O baths. Then the sections were 
submitted to Hydrogen Peroxide block during 10 
minutes. This process was repeated three times, 
and then the sections were washed three times in 
phosphate buffered saline (PBS) for 3 minutes each. 
The slides were submitted to antigen unmasking 
procedure by using Citrate Buffer (pH6.0) for 10 
minutes in a microwave oven, and after being heated, 
they were left at room temperature for 20 minutes. 
Later, they were washed with PBS and incubated in 
a humid chamber overnight at 4ºC, with antibodies 
diluted in PBS. The slides that received the anti-
PGRN antibody were incubated with positive control, 
and those that received the PBS with negative control. 
Afterwards, they were washed and incubated with 
biotinylated secondary antibodies during 15 minutes, 
followed by incubation with Streptavidin peroxidase 
complex (Dako-LSAB) during 30 min. The positive 
cells were seen after being stained with DAB (Dako) 
during 5 min. For the detection of HNF4α and 
PCNA antigens, the same procedure described above 
was used, differing only by the primary antibody 
utilized. For PCNA detection, the duodenum of the 
corresponding animal was used as positive control in 
the reaction. The photomicrographs were performed 
by KS400 4.4 ZEISS brand software. An OLYMPUS 
BX60 microscope and an AxioCam (ZEISS) camera 
were used for the procedure. 
Results
Immunohistochemistry for PGRN marking 
The immunohistochemistry for the marking of 
the expression of the PGRN protein, as well as for 
the other antibodies, was performed and repeated 
for all the embryonic stages proposed in this study. 
Anti-PGRN showed positivity in all the stages verified 
(Figure 1), whereas age E12.5 (Figure 1B) was less 
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Figure 1 -  Photomicrographs of immunohistochemistry + hematoxylin stain reaction for mark-
ing anti-progranulin (citoplasmatic immunereactivity) in the liver of Fischer 344 rat 
embryos at diff erent gestational stages (E12.5; E13.5; E14.5; E15.5 and E16.5). Control – 
negative control without antibody. Observe greater anti-progranulin positivity in E13.5. 
Bar: 150µm 
Fonte: (USP, São Paulo, 2012).
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positive to marking and the peak of positivity was at 
E13.5 (Figure 1D).
Immunohistochemistry for marking of HNF4α
Anti-HNF4α was also positive in the liver during 
all the embryonic stages studied (Figure 2). However, 
it was highly positive during stages E12.5; E13.5 and 
E14.5 (Figure 2B, D and F), and low during periods 
E15.5 and E16.5 (Figure 2H and J). The peak of 
positivity for anti-HNF4α was at E13.5 (Figure 2D). 
Immunohistochemistry for marking of PCNA 
Anti-PCNA was positive in all the embryonic stages 
observed (Figure 3). PCNA had its peak of positivity 
in E12.5 (Figure 3A) and lowest positivity in E13.5 
(Figure 3B).
Discussion
The results show primarily that PGRN is present in 
the liver during all the hepatogenic period studied, 
however, it shows less positivity in E12.5. Since the 
hepatogenesis threshold in rats is around E10.5 
(ELMAOUHOUB, 2006) when the anterior and 
posterior intestine become visible, the fact that PGRN 
is hardly present in the first stage studied (E12.5) 
demonstrates that this growth factor probably is not 
related to the beginning of liver development. The fact 
that the greatest positivity for PGRN is during E13.5, 
may suggest that there is a direct relation between liver 
undifferentiated stem cells, also called bipotential or 
hepatoblast cells, and PGRN. 
The hypothesis of this research was that PGRN 
stimulates cellular differentiation of hepatoblasts in 
hepatocytes during hepatogenesis. Corroborating this 
hypothesis with the result obtained, it is known that 
between E13.5-14.5 there is greater differentiation 
of hepatoblasts into hepatocytes and biliary 
epithelium cells (cholangiocytes) in mice (animals 
with embryonic development similar to that of rats) 
(MCLIN; ZORN, 2006). Furthermore, it is in these 
periods that greater morphologic cell differentiation 
of the liver bud occurs in rats (PASSOS, 2010). These 
results may suggest that PGRN acts direct or indirectly 
in differentiation of the hepatic cell lines.   
HNF4α is necessary for differentiation and 
development of hepatocytes (MAEDA et al., 
2006), and it was positive during all the process of 
hepatogenesis studied.  Knowing that in rats the liver 
bud begins to develop at E10 (ELMAOUHOUB, 
2006), and that HNF4α acts as a central regulator of 
hepatogenesis through the activation of the cascade 
of transcription factors that generate the final profile 
of gene expression in the mature hepatocyte (WATT; 
GARRISON; DUNCAN, 2003), it is really to be 
expected that this factor of transcription shows greater 
positivity during the beginning of the differentiation 
of hepatoblasts into hepatocytes in E12.5; E13.5 and 
E14.5, which happened in our study. 
Utilizing the study of Chen et al. (2010) as a base that 
demonstrates that the expression of HNF4α controls 
various specific genes of the liver which are necessary 
to liver differentiation, as well as to specific functions 
do mature liver, it can be supposed that the expression 
of HNF4α is directly connected to the activation of 
the expression of PGRN, keeping in mind that the 
increase of the positivity of PGRN (at E13.5) during 
the differentiation of hepatoblasts into hepatocytes is 
only observed 1 day after the expression of HNF4α at 
E12.5, and there is hardly any positivity of PRGN in 
this last period.
Thus, positivity of HNF4α during the embryonic 
ages studied and the synchrony of its peak of 
positivity with that of the PRGN, reinforces the idea 
that the HNF4α factor of transcription is essential to 
differentiation and development of hepatocytes, to the 
activation of liver-specific genes Chen et al. (2010), as 
well as to the activation of PGRN. 
The immunohistochemistry reaction for the 
marking of the PCNA protein was performed in 
order to verify the positivity of this protein present 
in the cell proliferation, since it is utilized as a marker 
of mitotic activity (NARYZHNY, 2008; STRZALKA; 
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Figure 2 - Photomicrographs of immunohistochemistry + hematoxylin stain reaction 
for marking anti-HNF4α (citoplasmatic immunereactivity) in the liver of 
Fischer 344 rat embryos at diff erent gestational stages (E12.5; E13.5; E14.5; 
E15.5 and E16.5). Control – negative control without antibody. Observe 
greater anti-HNF4α positivity between E12.5-E14.5. Bar: 150µm 
Fonte: (USP, São Paulo, 2012).
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Figure 3 - Photomicrographs of immunohistochemistry reaction for PCNA (nuclear immunereactivity) + he-
matoxylin stain in the liver of Fischer 344 rat embryos at diff erent gestational stages (E12.5; E13.5; 
E14.5; E15.5 and E16.5). Th e arrows represent nuclear positive marking for hepatocytes or hepato-
blasts. A liver demonstrating 2 lobes identifi ed in fi gure 3D. Observe greater anti-PCNA positivity in 
E12.5 (Figure 3A). Bar: A,B,C and E) 300µm; D) 1000µm; F) 150µm 
Fonte: (USP, São Paulo, 2012).
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ZIEMIENOWICZ, 2011). For this, the positivity 
sites of PCNA were compared to those of PGRN and 
HNF4α. PGRN has already been described as present 
in developing organs (LI et al., 1996; HE; BATEMAN, 
2003), including the liver (HE; BATEMAN, 2003), and 
as a growth factor and inductor of cell proliferation 
in the process of incubation, adhesion and growth of 
blastocysts (DANIEL et al., 2003; QIN et al., 2005). 
Thus, PGRN could also be acting in proliferation, and 
not only in differentiation of the developing liver. 
 The results demonstrated that there is a peak of 
PCNA positivity at E12.5, and that positivity is 
lower at the other periods. Since the embryo is in 
development, with high cell proliferation, and PGRN 
has already been described as precursor of cell 
proliferation (LI et al., 1996; DANIEL et al., 2003; 
HE; BATEMAN, 2003; QIN et al., 2005), a peak of 
positivity was expected for PCNA simultaneously 
with the peak for HNF4α and PGRN, thus showing 
that PGRN has a function in cell proliferation during 
hepatogenesis, and this did not happen. 
Thus, it seems that first there is a peak of cell 
proliferation at E12.5, which can be induced by 
HNF4α, which is highly positive from E12.5 to 
E14.5. Posteriorly there would be a peak of cellular 
differentiation at E13.5 compelled by PGRN after 
induction of HNF4α. Corroborating this hypothesis, 
both peaks of positivity for PGRN and HNF4α were 
at E13.5. Afterwards, (E14.5-E16.5), the levels of 
positivity for PGRN, HNF4α and PCNA diminished, 
coinciding with the period of maturation of the liver 
cells (PASSOS, 2010).
Conclusion
It can be concluded that PGRN is present in 
hepatogenesis in different embryonic stages of F344 
rats, and that it seems to be involved in the process of 
differentiation of hepatoblasts into hepatocytes after 
its activation by HNF4α, however, PGRN does not 
seem to assume a function of cell proliferation during 
hepatogenesis. Thus, it would be possible to use 
PGRN in future protocols of liver cell differentiation 
aimed as cellular therapy in Regenerative Medicine.
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